

Alessandra Vultaggio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6595037/publications.pdf>

Version: 2024-02-01

25
papers

823
citations

567281

15
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1454
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypersensitivity reactions to biologicals: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 39-54.	5.7	25
2	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	5.7	12
3	A Patient with Local Hypersensitivity Reactions to Three TNF- \pm Inhibitors and Local/Systemic Hypersensitivity Reactions to Tocilizumab: Desensitization to Tocilizumab. <i>Journal of Ankara University Faculty of Medicine</i> , 2022, 75, 130-133.	0.1	0
4	COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 871-874.	5.7	33
5	Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3340.	4.1	27
6	Effect of dupilumab treatment in a severe asthma patient with EGPA. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3824-3825.	3.8	10
7	Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors. <i>Biomedicines</i> , 2021, 9, 1497.	3.2	12
8	How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?. <i>Frontiers in Immunology</i> , 2021, 12, 765747.	4.8	8
9	Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2764-2774.	5.7	75
10	Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies. <i>Clinical Drug Investigation</i> , 2020, 40, 279-286.	2.2	3
11	COVID-19: general overview, pharmacological options and ventilatory support strategies. <i>Multidisciplinary Respiratory Medicine</i> , 2020, 15, 708.	1.5	2
12	Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis. <i>Allergy, Asthma and Immunology Research</i> , 2020, 12, 885.	2.9	29
13	The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2065-2072.e2.	3.8	18
14	Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?. <i>Respiratory Research</i> , 2018, 19, 113.	3.6	139
15	The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. <i>Respiratory Research</i> , 2018, 19, 154.	3.6	33
16	Biweekly Hizentra [®] in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS). <i>Journal of Clinical Immunology</i> , 2018, 38, 602-609.	3.8	11
17	Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. <i>International Immunopharmacology</i> , 2017, 44, 38-42.	3.8	13
18	Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies. <i>International Journal of Immunopathology and Pharmacology</i> , 2017, 30, 73-82.	2.1	21

#	ARTICLE	IF	CITATIONS
19	Hypersensitivity Reactions to Biologicals: True Allergy?. Current Treatment Options in Allergy, 2016, 3, 147-157.	2.2	4
20	Hypersensitivity Reactions to Biologic Agents. Immunology and Allergy Clinics of North America, 2014, 34, 615-632.	1.9	40
21	Assays and Strategies for Immunogenicity Assessment of Biological Agents. Drug Development Research, 2014, 75, S4-6.	2.9	19
22	Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clinical and Experimental Allergy, 2013, 43, n/a-n/a.	2.9	61
23	Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab. International Archives of Allergy and Immunology, 2012, 159, 321-326.	2.1	59
24	Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 262-268.	2.3	61
25	Acute infusion reactions induced by monoclonal antibody therapy. Expert Review of Clinical Immunology, 2011, 7, 55-63.	3.0	108